The Toxicity Profile of Concurrent Nivolumab and Ipilimumab
Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.
Clinical Pearls
Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the toxicity profile of concurrent nivolumab and ipilimumab as seen in a phase I trial.
- Additive toxicity was found between these agents.
- The grade 3/4 adverse event rate was greater than 50%.
- Most adverse events were reversible with immunosuppressants.
<<<
Recent Videos
Related Content
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025Article
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
